Gossamer Bio, Inc. ( NASDAQ:GOSS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts. The consensus estimated revenue ...

Stock analysts at Barrington Research boosted their FY2024 earnings estimates for VIZIO in a research report issued on ...

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...